Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer

Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We studied the safety and efficacy of the combination of these drugs in patients with advanced cancer. In all, 50 patients were enrolled. Captopril was given orally at a dose of 50 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, P H, Christodoulos, K, Dobbs, N, Thavasu, P, Balkwill, F, Blann, A D, Caine, G J, Kumar, S, Kakkar, A J, Gompertz, N, Talbot, D C, Ganesan, T S, Harris, A L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364746/
https://www.ncbi.nlm.nih.gov/pubmed/15162145
http://dx.doi.org/10.1038/sj.bjc.6601897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364746/
https://www.ncbi.nlm.nih.gov/pubmed/15162145
http://dx.doi.org/10.1038/sj.bjc.6601897

Ejemplares similares